Francis Giles

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Physiology

Neoplasm Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Giles Francis; Vey Norbert; DeAngelo Daniel; Seiter Karen; Stock Wendy; Stuart Robert; Boskovic Darinka; Pigneux Arnaud; Tallman Martin; Brandwein Joseph; Kell Jonathan; Robak Tadeusz; Staib Peter; Thomas Xavier; Cahill Ann; Albitar Maher; O'Brien Susan
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Mahalingam Devalingam; Mita Alain; Sankhala Kamalesh; Swords Ronan; Kelly Kevin; Giles Francis; Mita Monica M
Targeting sarcomas: novel biological agents and future perspectives.
Cortes Jorge E; Kantarjian Hagop M; Goldberg Stuart L; Powell Bayard L; Giles Francis J; Wetzler Meir; Akard Luke; Burke John M; Kerr Robert; Saleh Mansoor; Salvado August; McDougall Karen; Albitar Maher; Radich Jerald;
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Francis Giles (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Giles Francis; Vey Norbert; DeAngelo Daniel; Seiter Karen; Stock Wendy; Stuart Robert; Boskovic Darinka; Pigneux Arnaud; Tallman Martin; Brandwein Joseph; Kell Jonathan; Robak Tadeusz; Staib Peter; Thomas Xavier; Cahill Ann; Albitar Maher; O'Brien Susan
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood 2009;114(19):4027-33.
2009: Mahalingam Devalingam; Mita Alain; Sankhala Kamalesh; Swords Ronan; Kelly Kevin; Giles Francis; Mita Monica M
Targeting sarcomas: novel biological agents and future perspectives.
Current drug targets 2009;10(10):937-49.
2009: Cortes Jorge E; Kantarjian Hagop M; Goldberg Stuart L; Powell Bayard L; Giles Francis J; Wetzler Meir; Akard Luke; Burke John M; Kerr Robert; Saleh Mansoor; Salvado August; McDougall Karen; Albitar Maher; Radich Jerald;
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4754-9.
2009: Giles F J; O'Dwyer M; Swords R
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(10):1698-707.
2009: Giles Francis J
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
Leukemia research 2009;33(8):1022-3.
2009: Kelly Kevin; Nawrocki Steffan; Mita Alain; Coffey Matthew; Giles Francis J; Mita Monica
Reovirus-based therapy for cancer.
Expert opinion on biological therapy 2009;9(7):817-30.
2009: Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Jilani Iman; Donahue Amber C; Estey Elihu H; Kantarjian Hagop
Proteomics-based prediction of clinical response in acute myeloid leukemia.
Experimental hematology 2009;37(7):784-90.
2009: Mahalingam Devalingam; Kelly Kevin R; Swords Ronan T; Carew Jennifer; Nawrocki Steffan T; Giles Francis J
Emerging drugs in the treatment of pancreatic cancer.
Expert opinion on emerging drugs 2009;14(2):311-28.
2009: Ma Wanlong; Kantarjian Hagop; Bekele Benjamin; Donahue Amber C; Zhang Xi; Zhang Zhong J; O'Brien Susan; Estey Elihu; Estrov Zeev; Cortes Jorge; Keating Michael; Giles Francis; Albitar Maher
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3820-6.
2009: Mahalingam D; Swords R; Carew J S; Nawrocki S T; Bhalla K; Giles F J
Targeting HSP90 for cancer therapy.
British journal of cancer 2009;100(10):1523-9.
2009: Risinger April L; Giles Francis J; Mooberry Susan L
Microtubule dynamics as a target in oncology.
Cancer treatment reviews 2009;35(3):255-61.
2009: Giles Francis J
New directions in the treatment of imatinib failure and/or resistance.
Seminars in hematology 2009;46(2 Suppl 3):S27-33.
2009: Sankhala Kamalesh; Mita Alain; Kelly Kevin; Mahalingam Devalingam; Giles Francis; Mita Monica
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
Targeted oncology 2009;4(2):135-42.
2009: Kelly Kevin; Swords Ronan; Mahalingam Devalingam; Padmanabhan Swaminathan; Giles Francis J
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Targeted oncology 2009;4(2):99-105.
2009: Mahalingam Devalingam; Sankhala Kamalesh; Mita Alain; Giles Francis J; Mita Monica M
Targeting the mTOR pathway using deforolimus in cancer therapy.
Future oncology (London, England) 2009;5(3):291-303.
2009: Giles Francis J
The toxicities of modern targeted therapies: learning from the price of progress.
Targeted oncology 2009;4(2):65-6.
2009: Lee Tai-Sung; Ma Wanlong; Zhang Xi; Giles Francis; Kantarjian Hagop; Albitar Maher
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Cancer 2009;115(8):1692-700.
2009: Mahalingam Devalingam; Mita Alain; Mita Monica M; Nawrocki Steffan T; Giles Francis J
Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.
Current problems in cancer 2009;33(2):73-111.
2009: Abrahamsson Annelie E; Geron Ifat; Gotlib Jason; Dao Kim-Hien T; Barroga Charlene F; Newton Isabel G; Giles Francis J; Durocher Jeffrey; Creusot Remi S; Karimi Mobin; Jones Carol; Zehnder James L; Keating Armand; Negrin Robert S; Weissman Irving L; Jamieson Catriona H M
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(10):3925-9.
2009: Kelly Kevin; Swords Ronan; Kilcoyne Aoife; Sankhala Kamalesh; Mahalingam Devalingam; Padmanabhan Swaminathan; Giles Francis
Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
Leukemia & lymphoma 2009;50(2):297-9.
2009: Yeh Chen-Hsiung; Tseng Richard; Zhang Zhong; Cortes Jorge; O'Brien Susan; Giles Francis; Hannah Alison; Estrov Zeev; Keating Michael; Kantarjian Hagop; Albitar Maher
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Leukemia research 2009;33(2):212-7.
2009: Jilani I; Wei C; Bekele B N; Zhang Z J; Keating M; Wierda W; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien S M; Giles F J; Albitar M
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.
International journal of laboratory hematology 2009;31(1):97-105.
2009: Ma Wanlong; Kantarjian Hagop; Zhang Xi; Jilani Iman; Sheikholeslami Mohammad R; Donahue Amber C; Ravandi Farhad; Estey Elihu; O'Brien Susan; Keating Michael; Giles Francis J; Albitar Maher
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Cancer biomarkers : section A of Disease markers 2009;5(1):51-8.
2008: Schimmer Aaron D; O'Brien Susan; Kantarjian Hagop; Brandwein Joseph; Cheson Bruce D; Minden Mark D; Yee Karen; Ravandi Farhad; Giles Francis; Schuh Andre; Gupta Vikas; Andreeff Michael; Koller Charles; Chang Hong; Kamel-Reid Suzanne; Berger Mark; Viallet Jean; Borthakur Gautam
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(24):8295-301.
2008: Lee Tai-Sung; Ma Wanlong; Zhang Xi; Giles Francis; Cortes Jorge; Kantarjian Hagop; Albitar Maher
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Molecular cancer therapeutics 2008;7(12):3834-41.
2008: Mita Monica; Sankhala Kamalesh; Abdel-Karim Issam; Mita Alain; Giles Francis
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
Expert opinion on investigational drugs 2008;17(12):1947-54.
2008: Swords R; O'Rafferty C; Giles F; Browne P
Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(12):2277-8.
2008: Mahalingam Devalingam; Giles Francis
Challenges in developing targeted therapy for pancreatic adenocarcinoma.
Expert opinion on therapeutic targets 2008;12(11):1389-401.
2008: Nawrocki Steffan T; Carew Jennifer S; Maclean Kirsteen H; Courage James F; Huang Peng; Houghton Janet A; Cleveland John L; Giles Francis J; McConkey David J
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
Blood 2008;112(7):2917-26.
2008: Jones Dan; Thomas Deborah; Yin C Cameron; O'Brien Susan; Cortes Jorge E; Jabbour Elias; Breeden Megan; Giles Francis J; Zhao Weiqiang; Kantarjian Hagop M
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Cancer 2008;113(5):985-94.
2008: Carew Jennifer S; Giles Francis J; Nawrocki Steffan T
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Cancer letters 2008;269(1):7-17.
2008: Mita Alain C; Mita Monica M; Nawrocki Steffan T; Giles Francis J
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5000-5.
2008: Stock Wendy; Undevia Samir D; Bivins Carol; Ravandi Farhad; Odenike Olatoyosi; Faderl Stefan; Rich Elizabeth; Borthakur Gautam; Godley Lucy; Verstovsek Srdan; Artz Andrew; Wierda William; Larson Richard A; Zhang Yanming; Cortes Jorge; Ratain Mark J; Giles Francis J
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Abdel-Karim Isam A; Giles Francis J
Mammalian target of rapamycin as a target in hematological malignancies.
Current problems in cancer 2008;32(4):161-77.
2008: Borthakur Gautam; Alvarado Yesid; Ravandi-Kashani Farhad; Cortes Jorge; Estrov Zeev; Faderl Stefan; Ivy Percy; Bueso-Ramos Carlos; Nebiyou Bekele B; Giles Francis
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Cancer 2008;113(2):360-6.
2008: Carew Jennifer S; Nawrocki Steffan T; Giles Francis J; Cleveland John L
Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.
Biologics : targets & therapy 2008;2(2):201-4.
2008: Padmanabhan Swami; Ravella Saritha; Curiel Tyler; Giles Francis
Current status of therapy for chronic myeloid leukemia: a review of drug development.
Future oncology (London, England) 2008;4(3):359-77.
2008: Zhang H; Trachootham D; Lu W; Carew J; Giles F J; Keating M J; Arlinghaus R B; Huang P
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(6):1191-9.
2008: Jilani Iman; Kantarjian Hagop; Faraji Homan; Gorre Mercedes; Cortes Jorge; Ottmann Oliver; Bhalla Kapil; O'Brien Susan; Giles Francis; Albitar Maher
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Leukemia research 2008;32(6):936-43.
2008: Rizzieri David A; Feldman Eric; Dipersio John F; Gabrail Nashat; Stock Wendy; Strair Roger; Rivera Victor M; Albitar Maher; Bedrosian Camille L; Giles Francis J
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2756-62.
2008: Adams David J; Sandvold Marit L; Myhren Finn; Jacobsen Tove F; Giles Frank; Rizzieri David A
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Leukemia & lymphoma 2008;49(4):786-97.
2008: Ma Wanlong; Kantarjian Hagop; Zhang Xi; Sun Weimin; Buller Arlene M; Jilani Iman; Schwartz Joyce G; Giles Francis; Albitar Maher
Higher detection rate of JAK2 mutation using plasma.
Blood 2008;111(7):3906-7.
2008: Lee Tai-Sung; Potts Steven J; Kantarjian Hagop; Cortes Jorge; Giles Francis; Albitar Maher
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Cancer 2008;112(8):1744-53.
2008: Kennedy M P; Jimenez C A; Bruzzi J F; Mhatre A D; Lei X; Giles F J; Fanning T; Morice R C; Eapen G A
Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma.
Thorax 2008;63(4):360-5.
2008: Jilani Iman; Kantarjian Hagop; Gorre Mercedes; Cortes Jorge; Ottmann Oliver; Bhalla Kapil; Giles Francis J; Albitar Maher
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Leukemia research 2008;32(4):643-9.
2008: Ma Wanlong; Kantarjian Hagop; O'Brien Susan; Jilani Iman; Zhang Xi; Estrov Zeev; Ferrajoli Alessandra; Keating Michael; Giles Francis; Albitar Maher
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Cancer 2008;112(6):1306-12.
2008: Giles Francis J; DeAngelo Daniel J; Baccarani Michele; Deininger Michael; Guilhot François; Hughes Timothy; Mauro Michael; Radich Jerald; Ottmann Oliver; Cortes Jorge
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Seminars in oncology 2008;35(1 Suppl 1):S1-17; quiz S18-20.
2008: Verstovsek Srdan; Manshouri Taghi; Quintás-Cardama Alfonso; Harris David; Cortes Jorge; Giles Francis J; Kantarjian Hagop; Priebe Waldemar; Estrov Zeev
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):788-96.
2008: le Coutre Philipp; Ottmann Oliver G; Giles Francis; Kim Dong-Wook; Cortes Jorge; Gattermann Norbert; Apperley Jane F; Larson Richard A; Abruzzese Elisabetta; O'Brien Stephen G; Kuliczkowski Kazimierz; Hochhaus Andreas; Mahon Francois-Xavier; Saglio Giuseppe; Gobbi Marco; Kwong Yok-Lam; Baccarani Michele; Hughes Timothy; Martinelli Giovanni; Radich Jerald P; Zheng Ming; Shou Yaping; Kantarjian Hagop
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
2008: Kurzrock Razelle; Kantarjian Hagop M; Blascovich Michelle A; Bucher Cindy; Verstovsek Srdan; Wright John J; Pilat Susan R; Cortes Jorge E; Estey Elihu H; Giles Francis J; Beran Miloslav; Sebti Said M
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Brumlik Michael J; Daniel Benjamin J; Waehler Reinhard; Curiel David T; Giles Francis J; Curiel Tyler J
Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
Expert opinion on drug delivery 2008;5(1):87-103.
2008: Karp Judith E; Giles Francis J; Gojo Ivana; Morris Lawrence; Greer Jacqueline; Johnson Bonny; Thein Mya; Sznol Mario; Low Jennifer
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Leukemia research 2008;32(1):71-7.
2007: Borthakur Gautam; Lin E; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Giles Francis; Browning Mary L; Kantarjian Hagop; Keating Michael; O'Brien Susan
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Cancer 2007;110(11):2478-83.
2007: Cortes Jorge; Jabbour Elias; Kantarjian Hagop; Yin C Cameron; Shan Jianqin; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Breeden Megan; Reeves Nubia; Wierda William G; Jones Dan
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Blood 2007;110(12):4005-11.
2007: Jabbour Elias; Cortes Jorge; Giles Francis; Kantarjian Hagop
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Cancer journal (Sudbury, Mass.) 2007;13(6):357-65.
2007: Bareng Joanne; Jilani Iman; Gorre Mercedes; Kantarjian Hagop; Giles Francis; Hannah Alison; Albitar Maher
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
Leukemia & lymphoma 2007;48(11):2189-95.
2007: Jabbour Elias; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Richie Mary Ann; Beran Miloslav; Giles Francis; Verstovsek Srdan
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer 2007;110(9):2012-8.
2007: Cortes Jorge; Quintás-Cardama Alfonso; Garcia-Manero Guillermo; O'Brien Susan; Jones Dan; Faderl Stefan; Ebarb Theresa; Giles Francis; Thomas Deborah; Kantarjian Hagop
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Kantarjian Hagop M; Giles Francis; Gattermann Norbert; Bhalla Kapil; Alimena Giuliana; Palandri Francesca; Ossenkoppele Gert J; Nicolini Franck-Emmanuel; O'Brien Stephen G; Litzow Mark; Bhatia Ravi; Cervantes Francisco; Haque Ariful; Shou Yaping; Resta Debra J; Weitzman Aaron; Hochhaus Andreas; le Coutre Philipp
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Singer J B; Shou Y; Giles F; Kantarjian H M; Hsu Y; Robeva A S; Rae P; Weitzman A; Meyer J M; Dugan M; Ottmann O G
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(11):2311-5.
2007: Alvarado Yesid; Welch Mary Alma; Swords Ronan; Bruzzi John; Schlette Ellen; Giles Francis J
Nelarabine activity in acute biphenotypic leukemia.
Leukemia research 2007;31(11):1600-3.
2007: Soriano Andres O; Yang Hui; Faderl Stefan; Estrov Zeev; Giles Francis; Ravandi Farhad; Cortes Jorge; Wierda William G; Ouzounian Souzanne; Quezada Andres; Pierce Sherry; Estey Elihu H; Issa Jean-Pierre J; Kantarjian Hagop M; Garcia-Manero Guillermo
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Giles Francis J; Albitar Maher
Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.
Expert review of molecular diagnostics 2007;7(5):615-23.
2007: Giles Francis J
A new era for ribonucleoside reductase inhibition.
Leukemia research 2007;31(9):1163-4.
2007: Jabbour Elias; Cortes Jorge; Giles Francis; O'Brien Susan; Kantarijan Hagop
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
IDrugs : the investigational drugs journal 2007;10(7):468-79.
2007: Aribi Ahmed; Bueso-Ramos Carlos; Estey Eli; Estrov Zeev; O'Brien Susan; Giles Francis; Faderl Stefan; Thomas Deborah; Kebriaei Partow; Garcia-Manero Guillermo; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Giles Francis J; List Alan F; Carroll Michael; Cortes Jorge E; Valickas Joyce; Chen Bee-Lian; Masson Eric; Jacques Christian; Laurent Dirk; Albitar Maher; Feldman Eric J; Roboz Gail J
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Leukemia research 2007;31(7):891-7.
2007: Jabbour Elias; Cortes Jorge; Kantarjian Hagop; Giralt Sergio; Andersson Borje S; Giles Francis; Shpall Elizabeth; Kebriaei Partow; Champlin Richard; de Lima Marcos
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Cancer 2007;110(2):340-4.
2007: Pan J; Quintás-Cardama A; Manshouri T; Giles F J; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1395-404.
2007: Carew Jennifer S; Nawrocki Steffan T; Kahue Charissa N; Zhang Hui; Yang Chunying; Chung Linda; Houghton Janet A; Huang Peng; Giles Francis J; Cleveland John L
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
Blood 2007;110(1):313-22.
2007: Beran Miloslav; Wen Sijin; Shen Yu; Onida Francesco; Jelinek Jaroslav; Cortes Jorge; Giles Francis; Kantarjian Hagop
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.
Leukemia & lymphoma 2007;48(6):1150-60.
2007: Giles Francis J
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.
Leukemia & lymphoma 2007;48(6):1064-6.
2007: Swords R; Giles F
Troxacitabine in acute leukemia.
Hematology (Amsterdam, Netherlands) 2007;12(3):219-27.
2007: Jabbour Elias; Cortes Jorge E; Giles Francis J; O'Brien Susan; Kantarjian Hagop M
Current and emerging treatment options in chronic myeloid leukemia.
Cancer 2007;109(11):2171-81.
2007: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Koller Charles; Beran Miloslav; Giles Francis; Ravandi Farhad; Lerner Susan; Kantarjian Hagop; Keating Michael
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Leukemia research 2007;31(6):791-7.
2007: Alvarado Yesid; Giles Francis J
Ras as a therapeutic target in hematologic malignancies.
Expert opinion on emerging drugs 2007;12(2):271-84.
2007: Kantarjian Hagop; Giles Francis; List Alan; Lyons Roger; Sekeres Mikkael A; Pierce Sherry; Deuson Robert; Leveque Joseph
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Cancer 2007;109(9):1705-14.
2007: McKoy June M; Angelotta Cara; Bennett Charles L; Tallman Martin S; Wadleigh Martha; Evens Andrew M; Kuzel Timothy M; Trifilio Steve M; Raisch Dennis W; Kell Jonathan; DeAngelo Daniel J; Giles Francis J
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leukemia research 2007;31(5):599-604.
2007: Kantarjian Hagop; O'Brien Susan; Talpaz Moshe; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Rios Mary Beth; Shan Jianqin; Giles Francis; Cortes Jorge
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Zeng Zhihong; Sarbassov Dos D; Samudio Ismael J; Yee Karen W L; Munsell Mark F; Ellen Jackson C; Giles Francis J; Sabatini David M; Andreeff Michael; Konopleva Marina
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
Blood 2007;109(8):3509-12.
2007: Swords Ronan; Alvarado Yesid; Giles Francis
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S113-9.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Rios Mary Beth; Giles Francis; Kantarjian Hagop
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S51-7.
2007: Alvarado Yesid; Apostolidou Effrosyni; Swords Ronan; Giles Francis J
Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.
Expert opinion on emerging drugs 2007;12(1):165-79.
2007: Borthakur Gautam; O'Brien Susan; Wierda William G; Thomas Deborah A; Cortes Jorge E; Giles Francis J; Kantarjian Hagop M; Lerner Susan; Keating Michael J
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Albitar M; Johnson M; Do K A; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles F J
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):480-8.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Giles Francis; Thomas Deborah; Wierda William; Cortes Jorge
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Kantarjian Hagop M; Giles Francis; Quintás-Cardama Alfonso; Cortes Jorge
Important therapeutic targets in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1089-97.
2007: Ma Wanlong; Tseng Richard; Gorre Mercedes; Jilani Iman; Keating Michael; Kantarjian Hagop; Cortes Jorge; O'Brien Susan; Giles Francis; Albitar Maher
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Haematologica 2007;92(2):170-5.
2007: Giles Francis J; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Thomas Deborah; Wierda William; Ferrajoli Alessandra; Kornblau Steven; Pierce Sherry; Albitar Maher; Cortes Jorge; Kantarjian Hagop
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: Haritunians T; Mori A; O'Kelly J; Luong Q T; Giles F J; Koeffler H P
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(2):333-9.
2007: Albitar Maher; Vose Julie M; Johnson Marcella M; Do Kim-Ann; Day Amanda; Jilani Iman; Kantarjian Hagop; Keating Michael; O'Brien Susan M; Verstovsek Srdan; Armitage James O; Giles Francis J
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Leukemia research 2007;31(2):139-45.
2007: Vose Julie M; Panwalkar Amit; Belanger Robert; Coiffier Bertrand; Baccarani Michele; Gregory Stephanie A; Facon Thierry; Fanin Renato; Caballero Dolores; Ben-Yehuda Dina; Giles Francis
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Leukemia & lymphoma 2007;48(1):39-45.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Giles Francis; Kantarjian Hagop
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Seminars in hematology 2007;44(1 Suppl 1):S25-31.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Estrov Zeev; Giles Francis; Murgo Anthony; Ladie Nakia; Verstovsek Srdan; Cortes Jorge
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Roboz Gail J; Giles Francis J; Ritchie Ellen K; Allen-Bard Sandra; Curcio Tania J; Wilkes Meredith A; Park S Lani; Kantarjian Hagop M; Faderl Stefan; Ravandi Farhad; Kelner Michael J; Feldman Eric J
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):10-5.
2007: Giles Francis; Rizzieri David; Karp Judith; Vey Norbert; Ravandi Farhad; Faderl Stefan; Khan Khuda Dad; Verhoef Gregor; Wijermans Pierre; Advani Anjali; Roboz Gail; Kantarjian Hagop; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon M G J; Karsten Verena; Cahill Ann; Albitar Maher; Mufti Ghulam; O'Brien Susan
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2007: Giles Francis J; Cortes Jorge; Jones Dan; Bergstrom Donald; Kantarjian Hagop; Freedman Steven J
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Blood 2007;109(2):500-2.
2007: Quintas-Cardama Alfonso; Kantarjian Hagop; Jones Dan; Nicaise Claude; O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Blood 2007;109(2):497-9.
2007: Pan Jingxuan; Quintás-Cardama Alfonso; Kantarjian Hagop M; Akin Cem; Manshouri Taghi; Lamb Peter; Cortes Jorge E; Tefferi Ayalew; Giles Francis J; Verstovsek Srdan
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2007: Kantarjian Hagop; Oki Yasuhiro; Garcia-Manero Guillermo; Huang Xuelin; O'Brien Susan; Cortes Jorge; Faderl Stefan; Bueso-Ramos Carlos; Ravandi Farhad; Estrov Zeev; Ferrajoli Alessandra; Wierda William; Shan Jianqin; Davis Jan; Giles Francis; Saba Hussain I; Issa Jean-Pierre J
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2007: Apostolidou Effrosyni; Swords Ronan; Alvarado Yesid; Giles Francis J
Treatment of acute lymphoblastic leukaemia : a new era.
Drugs 2007;67(15):2153-71.
2007: Swords Ronan; Bruzzi John; Giles Francis
Recent advances in the diagnosis and therapy of Richter's syndrome.
Medical oncology (Northwood, London, England) 2007;24(1):17-32.
2007: Swords Ronan; Giles Francis
Hairy cell leukemia.
Medical oncology (Northwood, London, England) 2007;24(1):7-15.
2006: Kantarjian Hagop M; Talpaz Moshe; Giles Francis; O'Brien Susan; Cortes Jorge
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Verstovsek Srdan; Giles Francis; Quintás-Cardama Alfonso; Perez Nichole; Ravandi-Kashani Farhad; Beran Miloslav; Freireich Emil; Kantarjian Hagop
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Hematological oncology 2006;24(4):181-8.
2006: Verstovsek Srdan; Giles Francis J; Quintás-Cardama Alfonso; Manshouri Taghi; Huynh Ly; Manley Paul; Cortes Jorge; Tefferi Ayalew; Kantarjian Hagop
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Giles Francis J
FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Leukemia research 2006;30(12):1469-70.
2006: Giles Francis; Verstovsek Srdan; Faderl Stefan; Vey Norbert; Karp Judy; Roboz Gail; Khan Khuda Dan; Cooper Maureen; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon; Karsten Verena; Cahill Ann; Albitar Maher; Kantarjian Hagop; O'Brien Susan; Feldman Eric
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Ma W; Kantarjian H; Jilani I; Gorre M; Bhalla K; Ottmann O; Giles F; Albitar M
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(11):1989-91.
2006: Levis Mark; Brown Patrick; Smith B Douglas; Stine Adam; Pham Rosalyn; Stone Richard; Deangelo Daniel; Galinsky Ilene; Giles Frank; Estey Elihu; Kantarjian Hagop; Cohen Pamela; Wang Yanfeng; Roesel Johannes; Karp Judith E; Small Donald
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood 2006;108(10):3477-83.
2006: Verstovsek Srdan; Akin Cem; Manshouri Taghi; Quintás-Cardama Alfonso; Huynh Ly; Manley Paul; Tefferi Ayalew; Cortes Jorge; Giles Francis J; Kantarjian Hagop
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Swords Ronan; Apostolidou Effrosyni; Giles Francis
Troxacitabine in leukemia.
Hematology (Amsterdam, Netherlands) 2006;11(5):321-9.
2006: Jilani I; Keating M; Day A; William W; Kantarjian H; O'brien S; Giles F J; Albitar M
Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies.
Clinical and laboratory haematology 2006;28(5):325-31.
2006: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Jabbour Elias; Giles Francis; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Shan Jenny; Verstovsek Srdan; Cortes Jorge
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Quintas-Cardama Alfonso; Aribi Ahmed; Cortes Jorge; Giles Francis J; Kantarjian Hagop; Verstovsek Srdan
Novel approaches in the treatment of systemic mastocytosis.
Cancer 2006;107(7):1429-39.
2006: Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios M B; Verstovsek S; Cortes J
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(10):1767-73.
2006: Arana-Yi Cecilia; Quintás-Cardama Alfonso; Giles Francis; Thomas Deborah; Carrasco-Yalan Antonio; Cortes Jorge; Kantarjian Hagop; Verstovsek Srdan
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist 2006;11(8):929-43.
2006: Yee Karen W L; Zeng Zhihong; Konopleva Marina; Verstovsek Srdan; Ravandi Farhad; Ferrajoli Alessandra; Thomas Deborah; Wierda William; Apostolidou Efrosyni; Albitar Maher; O'Brien Susan; Andreeff Michael; Giles Francis J
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5165-73.
2006: Onciu Mihaela; Schlette Ellen; Zhou Yinmei; Raimondi Susana C; Giles Francis J; Kantarjian Hagop M; Medeiros L Jeffrey; Ribeiro Raul C; Pui Ching-Hon; Sandlund John T
Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.
Cancer 2006;107(5):1084-92.
2006: Orsolic Nada; Golemovic Mirna; Quintás-Cardama Alfonso; Scappini Barbara; Manshouri Taghi; Chandra Joya; Basic Ivan; Giles Francis; Kantarjian Hagop; Verstovsek Srdan
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Cancer science 2006;97(9):952-60.
2006: Quintás-Cardama A; Abruzzo L V; Giles F J; Jorgensen J; Cortes J; Sarriera J E; Kantarjian H; Verstovsek S
A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(9):1638-40.
2006: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Jones Daniel; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Ravandi Farhad; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Giles Francis; Fischer Thomas; Cortes Jorge; Garcia-Manero Guillermo; Beck Joachim; Ravandi Farhad; Masson Eric; Rae Patricia; Laird Glen; Sharma Sunil; Kantarjian Hagop; Dugan Margaret; Albitar Maher; Bhalla Kapil
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4628-35.
2006: Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M
Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
British journal of haematology 2006;134(3):341-3.
2006: Tefferi Ayalew; Cortes Jorge; Verstovsek Srdan; Mesa Ruben A; Thomas Deborah; Lasho Terra L; Hogan William J; Litzow Mark R; Allred Jacob B; Jones Dan; Byrne Catriona; Zeldis Jerome B; Ketterling Rhett P; McClure Rebecca F; Giles Francis; Kantarjian Hagop M
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood 2006;108(4):1158-64.
2006: Jabbour Elias; Cortes Jorge; Kantarjian Hagop M; Giralt Sergio; Jones Dan; Jones Roy; Giles Francis; Andersson Borje S; Champlin Richard; de Lima Marcos
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Blood 2006;108(4):1421-3.
2006: Koller Charles; Bekele B Nebiyou; Zhou Xian; Park Charles; Estrov Zeev; O'Brien Susan; Keating Michael; Jilani Iman; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
Blood 2006;108(3):1001-6.
2006: Sheikholeslami M R; Jilani I; Keating M; Uyeji J; Chen K; Kantarjian H; O'Brien S; Giles F; Albitar M
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Cytometry. Part B, Clinical cytometry 2006;70(4):270-5.
2006: Giles Francis; Verstovsek Srdan; Garcia-Manero Guillermo; Thomas Deborah; Ravandi Farhad; Wierda William; Ferrajoli Alessandra; Kornblau Steve; Jabbour Elias; Shan Jianqin; O'brien Susan; Albitar Maher; Kantarjian Hagop
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Moore Joseph; Seiter Karen; Kolitz Jonathan; Stock Wendy; Giles Francis; Kalaycio Matt; Zenk David; Marcucci Guido
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
Leukemia research 2006;30(7):777-83.
2006: Fiskus Warren; Pranpat Michael; Bali Purva; Balasis Maria; Kumaraswamy Sandhya; Boyapalle Sandhya; Rocha Kathy; Wu Jie; Giles Francis; Manley Paul W; Atadja Peter; Bhalla Kapil
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Blood 2006;108(2):645-52.
2006: Yee Karen W L; Cortes Jorge; Ferrajoli Alessandra; Garcia-Manero Guillermo; Verstovsek Srdan; Wierda William; Thomas Deborah; Faderl Stefan; King Ivan; O'brien Susan M; Jeha Sima; Andreeff Michael; Cahill Ann; Sznol Mario; Giles Francis J
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Leukemia research 2006;30(7):813-22.
2006: Faderl Stefan; Verstovsek Srdan; Cortes Jorge; Ravandi Farhad; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; O'Brien Susan; Koller Charles; Giles Francis J; Wierda William; Kwari Monica; Kantarjian Hagop M
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Giles Francis J; Bellamy William T; Estrov Zeev; O'Brien Susan M; Verstovsek Srdan; Ravandi Farhad; Beran Miloslav; Bycott Paul; Pithavala Yazdi; Steinfeldt Heidi; Reich Steven D; List Alan F; Yee Karen W L
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leukemia research 2006;30(7):801-11.
2006: Quintás-Cardama Alfonso; Kantarjian Hagop M; Giles Francis; Verstovsek Srdan
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):409-16.
2006: Kantarjian Hagop; Giles Francis; Wunderle Lydia; Bhalla Kapil; O'Brien Susan; Wassmann Barbara; Tanaka Chiaki; Manley Paul; Rae Patricia; Mietlowski William; Bochinski Kathy; Hochhaus Andreas; Griffin James D; Hoelzer Dieter; Albitar Maher; Dugan Margaret; Cortes Jorge; Alland Leila; Ottmann Oliver G
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Giles F J
Clone wars in CML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):939-40.
2006: Ma W; Jilani I; Gorre M; Keating M; Chan H; Tseng R; Kantarjian H; O'Brien S; Giles F J; Albitar M
Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia.
British journal of haematology 2006;133(6):690-2.
2006: Roboz G J; Giles F J; List A F; Cortes J E; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster M W; Laurent D; Feldman E J
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):952-7.
2006: Ravandi Farhad; Jorgensen Jeffrey L; O'Brien Susan M; Verstovsek Srdan; Koller Charles A; Faderl Stefan; Giles Francis J; Ferrajoli Alessandra; Wierda William G; Odinga Shirley; Huang Xuelin; Thomas Deborah A; Freireich Emil J; Jones Dan; Keating Michael J; Kantarjian Hagop M
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Yee Karen W L; Hymes Sharon R; Heller Lior; Prieto Victor G; Welch Mary Alma; Giles Francis J
Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature.
Leukemia & lymphoma 2006;47(5):926-9.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Khouri Issa; Giles Francis J; Kantarjian Hagop M; Champlin Richard; Wen Sijin; Do Kim-Anh; Smith Susan C; Lerner Susan; Freireich Emil J; Keating Michael J
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Hock Barry D; McKenzie Judith L; Patton Nigel W; Drayson Mark; Taylor Karen; Wakeman Chris; Kantarjian Hagop; Giles Francis; Albitar Maher
Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Cancer 2006;106(10):2148-57.
2006: Thomas Deborah A; Giles Francis J; Albitar Maher; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; O'Brien Susan M; Garcia-Manero Guillermo; Keating Michael J; Pierce Sherry; Zeldis Jerome; Kantarjian Hagop M
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Lee Carlton K K; Rowinsky Eric K; Li Jing; Giles Francis; Moore Malcolm J; Hidalgo Manuel; Capparelli Edmund; Jolivet Jacques; Baker Sharyn D
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2158-65.
2006: Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Keating Michael; Thomas Deborah; Clarke Charlotte; Jilani Iman; Aguilar Christine; Estey Elihu; Kantarjian Hagop
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
Cancer 2006;106(7):1587-94.
2006: Thomas Deborah A; Faderl Stefan; O'Brien Susan; Bueso-Ramos Carlos; Cortes Jorge; Garcia-Manero Guillermo; Giles Francis J; Verstovsek Srdan; Wierda William G; Pierce Sherry A; Shan Jianqin; Brandt Mark; Hagemeister Fredrick B; Keating Michael J; Cabanillas Fernando; Kantarjian Hagop
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Aribi Ahmed; Ravandi Farhad; Giles Frank
Novel agents in acute myeloid leukemia.
Cancer journal (Sudbury, Mass.) 2006;12(2):77-91.
2006: Vey Norbert; Giles Frank
Cloretazine for the treatment of acute myeloid leukemia.
Expert review of anticancer therapy 2006;6(3):321-8.
2006: Ault Patricia; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Beran Miloslav; Rios Mary Beth; Koller Charles; Giles Francis; Keating Michael; Talpaz Moshe; Cortes Jorge
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Kantarjian Hagop; Beran Miloslav; Cortes Jorge; O'Brien Susan; Giles Francis; Pierce Sherry; Shan Jianqin; Plunkett William; Keating Michael; Estey Elihu
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Kantarjian Hagop; O'brien Susan; Cortes Jorge; Giles Francis; Faderl Stefan; Jabbour Elias; Garcia-Manero Guillermo; Wierda William; Pierce Sherry; Shan Jianqin; Estey Elihu
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Tsimberidou Apostolia-Maria; Giles Francis J; Estey Elihu; O'Brien Susan; Keating Michael J; Kantarjian Hagop M
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Mattiuzzi Gloria N; Alvarado Gladys; Giles Francis J; Ostrosky-Zeichner Luis; Cortes Jorge; O'brien Susan; Verstovsek Srdan; Faderl Stefan; Zhou Xian; Raad Issam I; Bekele B Nebiyou; Leitz G J; Lopez-Roman Ivonne; Estey Elihu H
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2006: Wierda William; O'brien Susan; Faderl Stefan; Ferrajoli Alessandra; Wang Xuemei; Do Kim-Anh; Garcia-Manero Guillermo; Thomas Deborah; Cortes Jorge; Ravandi-Kashani Farhad; Giles Francis; Lerner Susan; Kantarjian Hagop; Keating Michael
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2006: Borthakur Gautam; Kantarjian Hagop; Daley George; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; Sugrue Mary; Cortes Jorge
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2006: Thomas Deborah A; Sarris Andreas H; Cortes Jorge; Faderl Stefan; O'Brien Susan; Giles Francis J; Garcia-Manero Guillermo; Rodriguez Maria A; Cabanillas Fernando; Kantarjian Hagop
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Cancer 2006;106(1):120-7.
2006: Heidel Florian; Solem Fian K; Breitenbuecher Frank; Lipka Daniel B; Kasper Stefan; Thiede M H; Brandts Christian; Serve Hubert; Roesel Johannes; Giles Francis; Feldman Eric; Ehninger Gerhard; Schiller Gary J; Nimer Stephen; Stone Richard M; Wang Yanfeng; Kindler Thomas; Cohen Pamela S; Huber Christoph; Fischer Thomas
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Blood 2006;107(1):293-300.
2005: Yee Karen W L; Jabbour Elias; Kantarjian Hagop M; Giles Francis J
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Annals of hematology 2005;84 Suppl 1():18-24.
2005: Xu R-H; Pelicano H; Zhang H; Giles F J; Keating M J; Huang P
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(12):2153-8.
2005: Faderl Stefan; Do Kim-Anh; Johnson Marcella M; Keating Michael; O'brien Susan; Jilani Iman; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Aguilar Christine; Dey Amanda; Thomas Deborah A; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
Blood 2005;106(13):4303-7.
2005: Ravandi Farhad; O'Brien Susan; Jones Dan; Lerner Susan; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Garcia-Manero Guillermo; Thomas Deborah; Koller Charles; Verstovsek Srdan; Giles Francis; Cortes Jorge; Herling Marco; Kantarjian Hagop; Keating Michael
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: O'Brien Susan; Albitar Maher; Giles Francis J
Monoclonal antibodies in the treatment of leukemia.
Current molecular medicine 2005;5(7):663-75.
2005: Giles Francis J; Albitar Maher
Mammalian target of rapamycin as a therapeutic target in leukemia.
Current molecular medicine 2005;5(7):653-61.
2005: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Current molecular medicine 2005;5(7):615-23.
2005: Giles Francis J
Targeted therapy in hematologic maligancies--progress made, lessons learned?
Current molecular medicine 2005;5(7):607.
2005: Giles Francis; Verstovsek Srdan; Thomas Deborah; Gerson Stanton; Cortes Jorge; Faderl Stefan; Ferrajoli Alessandra; Ravandi Farhad; Kornblau Steven; Garcia-Manero Guillermo; Jabbour Elias; O'Brien Susan; Karsten Verena; Cahill Ann; Yee Karen; Albitar Maher; Sznol Mario; Kantarjian Hagop
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Mattiuzzi Gloria; Giles Francis J
Management of intracranial fungal infections in patients with haematological malignancies.
British journal of haematology 2005;131(3):287-300.
2005: Yee Karen W L; Hagey Anne; Verstovsek Srdan; Cortes Jorge; Garcia-Manero Guillermo; O'Brien Susan M; Faderl Stefan; Thomas Deborah; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Albitar Maher; McKeegan Evelyn; Grimm David R; Mueller Toby; Holley-Shanks Rhonda R; Sahelijo Leonardo; Gordon Gary B; Kantarjian Hagop M; Giles Francis J
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Verstovsek Srdan; Golemovic Mirna; Kantarjian Hagop; Manshouri Tashi; Estrov Zeev; Manley Paul; Sun Tong; Arlinghaus Ralph B; Alland Leila; Dugan Margaret; Cortes Jorge; Giles Francis; Beran Miloslav
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Cancer 2005;104(6):1230-6.
2005: Amin H M; Yang Y; Shen Y; Estey E H; Giles F J; Pierce S A; Kantarjian H M; O'Brien S M; Jilani I; Albitar M
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1567-72.
2005: Jabbour Elias; Verstovsek Srdan; Giles Francis; Gandhi Varsha; Cortes Jorge; O'Brien Susan; Plunkett William; Garcia-Manero Guillermo; Jackson C Ellen; Kantarjian Hagop; Andreeff Michael
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Giles Francis; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Bueso-Ramos Carlos; Shan Jianqin; Pierce Sherry; Garcia-Manero Guillermo; Keating Michael; Kantarjian Hagop
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Wierda William; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Shan Jianqin; Cortes Jorge
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Golemovic Mirna; Verstovsek Srdan; Giles Francis; Cortes Jorge; Manshouri Taghi; Manley Paul W; Mestan Jürgen; Dugan Margaret; Alland Leila; Griffin James D; Arlinghaus Ralph B; Sun Tong; Kantarjian Hagop; Beran Miloslav
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4941-7.
2005: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Faderl Stephan; Verstovsek Srdan; Thomas Deborah; Garcia-Manero Guillermo; Wierda William; Ferrajoli Alessandra; Kornblau Stephen; Mattiuzzi Gloria N; Tsimberidou Apostolia M; Albitar Maher; O'Brien Susan M; Estey Elihu
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Saba Rashid; Jabbour Elias; Giles Francis; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Freireich Emil J; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Wierda William; O'Brien Susan; Wen Sijin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah; Do Kim-Anh; Cortes Jorge; Koller Charles; Beran Miloslav; Ferrajoli Alessandra; Giles Francis; Lerner Susan; Albitar Maher; Kantarjian Hagop; Keating Michael
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2005: Yee Karen W L; O'Brien Susan M; Giles Francis J
Richter's syndrome: biology and therapy.
Cancer journal (Sudbury, Mass.) 2005;11(3):161-74.
2005: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Jones Dan; Luthra Rajyalakshmi; Shan Jenny; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Rios Mary B; Kantarjian Hagop
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Jabbour Elias J; Giles Francis J
New agents in myelodysplastic syndromes.
Current hematology reports 2005;4(3):191-9.
2005: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Shan Jianqin; Rios Mary Beth; Champlin Richard; de Lima Marcos; Cortes Jorge
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Cortes Jorge; Faderl Stefan; Estey Elihu; Kurzrock Razelle; Thomas Deborah; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Giles Francis; Koller Charles; O'Brien Susan; Wright John; Bai Stephen A; Kantarjian Hagop
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2005: Tsimberidou A-M; Giles F J; Khouri I; Bueso-Ramos C; Pilat S; Thomas D A; Cortes J; Kurzrock R
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):139-45.
2005: Hennessy Bryan T; Thomas Deborah A; Giles Francis J; Kantarjian Hagop; Verstovsek Srdan
New approaches in the treatment of myelofibrosis.
Cancer 2005;103(1):32-43.
2005: Giles Francis
Gemtuzumab ozogamicin: a component of induction therapy in AML?
Leukemia research 2005;29(1):1-2.
2005: Kindler Thomas; Breitenbuecher Frank; Kasper Stefan; Estey Eli; Giles Francis; Feldman Eric; Ehninger Gerhard; Schiller Gary; Klimek Virginia; Nimer Stephen D; Gratwohl Alois; Choudhary Chuna Ram; Mueller-Tidow Constan; Serve Hubert; Gschaidmeier Harald; Cohen Pamela S; Huber Christoph; Fischer Thomas
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood 2005;105(1):335-40.
2004: Kantarjian Hagop; Thomas Deborah; O'Brien Susan; Cortes Jorge; Giles Francis; Jeha Sima; Bueso-Ramos Carlos E; Pierce Sherry; Shan Jianqin; Koller Charles; Beran Miloslav; Keating Michael; Freireich Emil J
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Cancer 2004;101(12):2788-801.
2004: Jilani Iman; Keating Michael; Giles Francis J; O'Brien Susan; Kantarjian Hagop M; Albitar Maher
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.
Leukemia research 2004;28(12):1255-62.
2004: Hennessy Bryan; Giles Francis; Cortes Jorge; O'brien Susan; Ferrajoli Alessandra; Ossa Gladys; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop; Verstovsek Srdan
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: Sun X; Amin H M; Freireich E J; Keating M J; Kantarjian H M; Koller C A; O'Brien S M; Giles F; Albitar M
Hairy cell leukemia with large cells: long disease course with adequate response to therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(11):1912-4.
2004: Wang Zhiqing; Zhang Yana; Mandal Arabinda; Zhang Jian; Giles Francis J; Herr John C; Lim Seah H
The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6544-50.
2004: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Luthra Rajyalakshmi; Giles Francis; Verstovsek Srdan; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Jones Dan; Talpaz Moshe
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Albitar Maher; Do Kim-Anh; Johnson Marcella M; Giles Francis J; Jilani Iman; O'Brien Susan; Cortes Jorge; Thomas Deborah; Rassenti Laura Z; Kipps Thomas J; Kantarjian Hagop M; Keating Michael
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Cancer 2004;101(5):999-1008.
2004: Tsimberidou Apostolia-Maria; Estey Elihu; Whitman Gary J; Dryden Mark J; Ratnam Suresh; Pierce Sherry; Faderl Stefan; Giles Francis; Kantarjian Hagop M; Garcia-Manero Guillermo
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leukemia research 2004;28(9):991-4.
2004: Thomas Deborah A; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Beran Miloslav; Pierce Sherry; Ha Chul S; Cabanillas Fernando; Keating Michael J; Kantarjian Hagop
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Tsimberidou Apostolia-Maria; Giles Francis J; Duvic Madeleine; Kurzrock Razelle
Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
Journal of the American Academy of Dermatology 2004;51(2):200-4.
2004: Bueso-Ramos Carlos E; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Medeiros L Jeffrey; Kantarjian Hagop
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Cancer 2004;101(2):332-6.
2004: Yee Karen W L; O'Brien Susan M; Giles Francis J
An update on the management of chronic lymphocytic leukaemia.
Expert opinion on pharmacotherapy 2004;5(7):1535-54.
2004: Verstovsek Srdan; Giles Francis J; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: O'Farrell Anne-Marie; Yuen Helene A; Smolich Beverly; Hannah Alison L; Louie Sharianne G; Hong Weiru; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Karp Judith E; Albitar Maher; Cherrington Julie M; Giles Francis J
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M; O'Brien Susan M
Accelerated and blastic phases of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):753-74, xii.
2004: Cortes Jorge E; O'Brien Susan M; Giles Francis; Alvarez Ricardo H; Talpaz Moshe; Kantarjian Hagop M
Investigational strategies in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):619-39, ix.
2004: Colburn Dawn E; Giles Francis J; Oladovich Debra; Smith Judith A
In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
Hematology (Amsterdam, Netherlands) 2004;9(3):217-21.
2004: Tsimberidou Apostolia M; Keating Michael J; Giles Francis J; Wierda William G; Ferrajoli Alessandra; Lerner Susan; Beran Miloslav; Andreeff Michael; Kantarjian Hagop M; O'Brien Susan
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2004: Cortes Jorge; O'Brien Susan; Quintas Alfonso; Giles Francis; Shan Jianquin; Rios Mary Beth; Talpaz Moshe; Kantarjian Hagop
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cancer 2004;100(11):2396-402.
2004: Ault Patricia; Kantarjian Hagop; Welch Mary Alma; Giles Francis; Rios Mary Beth; Cortes Jorge
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Leukemia research 2004;28(6):613-8.
2004: Giles Francis J; Vose Julie M; Do Kim-Anh; Johnson Marcella M; Manshouri Taghi; Bociek Gregory; Bierman Philip J; O'Brien Susan M; Kantarjian Hagop M; Armitage James O; Albitar Maher
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Leukemia research 2004;28(6):595-604.
2004: Giles Francis J; Rodriguez Roberto; Weisdorf Daniel; Wingard John R; Martin Paul J; Fleming Thomas R; Goldberg Stuart L; Anaissie Elias J; Bolwell Brian J; Chao Nelson J; Shea Thomas C; Brunvand Mark M; Vaughan William; Petersen Finn; Schubert Mark; Lazarus Hillard M; Maziarz Richard T; Silverman Margarida; Beveridge Roy A; Redman Rebecca; Pulliam Janis G; Devitt-Risse Patricia; Fuchs Henry J; Hurd David D
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.
Leukemia research 2004;28(6):559-65.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Cortes Jorge; Thomas Deborah; Koller Charles; Giles Francis; Estey Elihu; Faderl Stefan; Garcia-Manero Guillermo; McConkey David; Ruiz Stacey L; Guerciolini Roberto; Wright John; Kantarjian Hagop
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3371-6.
2004: Ma Yupo; Mansour Adnan; Bekele B Nebiyou; Zhou Xian; Keating Michael J; O'Brien Susan; Giles Francis J; Albitar Maher
The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia.
Cancer 2004;100(10):2167-75.
2004: Giles Francis; Thomas Deborah; Garcia-Manero Guillermo; Faderl Stefan; Cortes Jorge; Verstovsek Srdan; Ferrajoli Alessandra; Jeha Sima; Beran Miloslav; Koller Charles; Andreeff Michael; Cahill Ann; Clairmont Caroline; Sznol Mario; Kantarjian Hagop
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2908-17.
2004: Hu Qinglong; Dey Amanda L; Yang Ying; Shen Yu; Jilani Iman B; Estey Elihu H; Kantarjian Hagop M; Giles Francis J; Albitar Maher
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer 2004;100(9):1884-91.
2004: Albitar Maher; Zhou Weidong; Giles Francis
Myelodysplastic syndrome: from morphology to biology.
Current hematology reports 2004;3(3):159-64.
2004: Smith B Douglas; Levis Mark; Beran Miloslav; Giles Francis; Kantarjian Hagop; Berg Karin; Murphy Kathleen M; Dauses Tianna; Allebach Jeffrey; Small Donald
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Blood 2004;103(10):3669-76.
2004: Tsao Anne S; Kantarjian Hagop; Thomas Deborah; Giles Francis; Cortes Jorge; Garcia-Manero Guillermo; Huh Yang; Yang Ying; Shen Yu; Albitar Maher; Estey Elihu
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.
Leukemia research 2004;28(4):373-8.
2004: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M; O'Brien Susan M; Estey Elihu; Beran Miloslav
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Leukemia research 2004;28(4):353-7.
2004: Panwalkar Amit; Verstovsek Srdan; Giles Francis
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.
Cancer 2004;100(8):1578-89.
2004: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Giles Francis; Rios Mary Beth; Shan Jianqin; Letvak Laurie; Thomas Deborah; Faderl Stefan; Ferrajoli Alessandra; Cortes Jorge
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: El-Zimaity Maha M T; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Thomas Deborah; Ferrajoli Alessandra; Hayes Kimberly; Nebiyou Bekele B; Zhou Xian; Rios Mary B; Glassman Armand B; Cortes Jorge E
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
British journal of haematology 2004;125(2):187-95.
2004: Giles Francis J; Kantarjian Hagop; Cortes Jorge
Novel therapies for patients with chronic myeloid leukemia.
Expert review of anticancer therapy 2004;4(2):271-82.
2004: Kurzrock Razelle; Albitar Maher; Cortes Jorge E; Estey Elihu H; Faderl Stefan H; Garcia-Manero Guillermo; Thomas Deborah A; Giles Francis J; Ryback Mary Ellen; Thibault Alain; De Porre P; Kantarjian Hagop M
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Giles Francis J; Tallman Martin S; Garcia-Manero Guillermo; Cortes Jorge E; Thomas Deborah A; Wierda William G; Verstovsek Srdan; Hamilton Marta; Barrett Emma; Albitar Maher; Kantarjian Hagop M
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Rogers Anna; Joe Youngson; Manshouri Taghi; Dey Amanda; Jilani Iman; Giles Francis; Estey Elihu; Freireich Emil; Keating Michael; Kantarjian Hagop; Albitar Maher
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
Blood 2004;103(7):2799-801.
2004: Orsolic Nada; Giles Francis J; Gourdeau Henriette; Golemovic Mirna; Beran Miloslav; Cortes Jorge; Freireich Emil J; Kantarjian Hagop; Verstovsek Srdan
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
British journal of haematology 2004;124(6):727-38.
2004: Issa Jean-Pierre J; Garcia-Manero Guillermo; Giles Francis J; Mannari Rajan; Thomas Deborah; Faderl Stefan; Bayar Emel; Lyons John; Rosenfeld Craig S; Cortes Jorge; Kantarjian Hagop M
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood 2004;103(5):1635-40.
2004: Panwalkar Amit; Verstovsek Srdan; Giles Francis J
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Cancer 2004;100(4):657-66.
2004: Tsimberidou Apostolia-Maria; Giles Francis; Romaguera Jorge; Duvic Madeleine; Kurzrock Razelle
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Cancer 2004;100(3):574-80.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; O'Brien Susan; Kontoyiannis Dimitrios P; Giles Francis; Zhou Xian; Lim JoAnn; Bekele B Nebiyou; Faderl Stefan; Cortes Jorge; Pierce Sherry; Leitz Gerhard J; Raad Issam; Estey Elihu
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Ravandi Farhad; Kantarjian Hagop; Giles Francis; Cortes Jorge
New agents in acute myeloid leukemia and other myeloid disorders.
Cancer 2004;100(3):441-54.
2004: Zangari Maurizio; Anaissie Elias; Stopeck Alison; Morimoto Alyssa; Tan Nguyen; Lancet Jeffrey; Cooper Maureen; Hannah Alison; Garcia-Manero Guillermo; Faderl Stephan; Kantarjian Hagop; Cherrington Julie; Albitar Maher; Giles Francis J
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2004: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Shan Jianqin; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Keating Michael; Talpaz Moshe
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2004: Tsimberidou Apostolia-Maria; Giles Francis; Duvic Madeleine; Fayad Luis; Kurzrock Razelle
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Cancer 2004;100(2):342-9.
2004: Sneed Thomas B; Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Rios Mary Beth; Bekele B Nebiyou; Zhou Xian; Resta Debra; Wierda William; Faderl Stefan; Giles Francis; Cortes Jorge E
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2003: O'Brien Susan M; Kantarjian Hagop M; Thomas Deborah A; Cortes Jorge; Giles Francis J; Wierda William G; Koller Charles A; Ferrajoli Alessandra; Browning Mary; Lerner Susan; Albitar Maher; Keating Michael J
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Keating Michael; Talpaz Moshe
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Hennessy Bryan T; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J
DNA methylation in haematological malignancies: the role of decitabine.
Expert opinion on investigational drugs 2003;12(12):1985-93.
2003: Giles Francis J; Vose Julie M; Do Kim-Anh; Johnson Marcella M; Manshouri Taghi; Bociek Gregory; Bierman Philip J; O'Brien Susan M; Keating Michael J; Kantarjian Hagop M; Armitage James O; Albitar Maher
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
British journal of haematology 2003;123(5):850-7.
2003: Tsimberidou Apostolia M; Estey Elihu; Cortes Jorge E; Garcia-Manero Guillermo; Faderl Stefan; Verstovsek Srdan; Thomas Deborah A; Ferrajoli Alessandra; Keating Michael J; O'Brien Susan; Kantarjian Hagop M; Giles Francis J
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Giles Francis J; Feldman Eric J; Roboz Gail J; Larson Richard A; Mamus Steven W; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; Talpaz Moshe; Beran Miloslav; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Giles Francis J; Fracasso Paula M; Kantarjian Hagop M; Cortes Jorge E; Brown Randy A; Verstovsek Srdan; Alvarado Yesid; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Wright Lisa P; Samson Tom; Cahill Ann; Lambert Paula; Plunkett William; Sznol Mario; DiPersio John F; Gandhi Varsha
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Thomas Deborah A; O'Brien Susan; Bueso-Ramos Carlos; Faderl Stefan; Keating Michael J; Giles Francis J; Cortes Jorge; Kantarjian Hagop M
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Thomas Deborah A; Estey Elihu; Giles Francis J; Faderl Stefan; Cortes Jorge; Keating Michael; O'Brien Susan; Albitar Maher; Kantarjian Hagop
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
British journal of haematology 2003;123(3):436-41.
2003: Giles Francis; Estey Elihu; O'Brien Susan
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Cancer 2003;98(10):2095-104.
2003: Zhang Yana; Wang Zhiqing; Liu Haichao; Giles Francis J; Lim Seah H
Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(6):461-7.
2003: Medina Jorge; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Rios Mary Beth; Hayes Kimberly; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Cancer 2003;98(9):1905-11.
2003: Yazji S; Giles F J; Tsimberidou A-M; Estey E H; Kantarjian H M; O'Brien S A; Kurzrock R
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(11):2101-6.
2003: Jilani Iman; O'Brien Susan; Manshuri Taghi; Thomas Deborah A; Thomazy Vilmos A; Imam Maha; Naeem Sana; Verstovsek Srdan; Kantarjian Hagop; Giles Francis; Keating Michael; Albitar Maher
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
Blood 2003;102(10):3514-20.
2003: Tomkinson Blake; Bendele Ray; Giles Francis J; Brown Eric; Gray Atherton; Hart Karen; LeRay Jeremy D; Meyer Denny; Pelanne Michelle; Emerson David L
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
Leukemia research 2003;27(11):1039-50.
2003: Cortes Jorge; Giles Francis
New agents in chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1(4):501-12.
2003: Tsimberidou Apostolia M; Giles Francis J; Kantarjian Hagop M; Keating Michael J; O'Brien Susan M
Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Leukemia & lymphoma 2003;44(10):1719-25.
2003: Onciu Mihaela; Estey Elihu; Giles Francis J
Circulating blasts following chemotherapy in pediatric patients: implications for complete remission definition in acute leukemia.
Hematology (Amsterdam, Netherlands) 2003;8(5):295-301.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorges; Shan Jianqin; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Rios Mary Beth; Talpaz Moshe
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Lee Jeong N; Giles Fancis; Huh Yang O; Manshouri Taghi; O'Brien Susan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.
European journal of haematology 2003;71(4):235-42.
2003: Tsimberidou Apostolia; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stephan; Albitar Maher; Kantarjian Hagop; Estey Elihu; Giles Francis J
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Apostolidou Efrosyni; Cortes Jorge; Tsimberidou Apostolia; Estey Elihu; Kantarjian Hagop; Giles Francis J
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Leukemia research 2003;27(10):887-91.
2003: Kantarjian Hagop; Gandhi Varsha; Cortes Jorge; Verstovsek Srdan; Du Min; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; O'Brien Susan; Jeha Sima; Davis Jan; Shaked Zeev; Craig Adam; Keating Michael; Plunkett William; Freireich Emil J
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood 2003;102(7):2379-86.
2003: Beran Miloslav; O'Brien Susan; Thomas Deborah A; Tran Hai T; Cortes-Franco Jorge E; Giles Francis; Estey Elihu; Kantarjian Hagop M
Phase I study of oral topotecan in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4084-91.
2003: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Beth Rios Mary; Shan Jianquin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge; Rios Mary Beth; Shan Jianqin; Thomas Deborah; Andreeff Michael; Kornblau Steven; Faderl Stefan; Garcia-Manero Guillermo; White Kevin; Mallard Susie; Freireich Emil; Kantarjian Hagop M
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Ahmed Maha; Giles Francis; Joe Youngson; Weber Donna M; Jilani Iman; Manshouri Taghi; Giralt Sergio; De Lima Marcos; Keating Michael; Albitar Maher
Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.
European journal of haematology 2003;71(3):174-8.
2003: Giles Francis J; Cortes Jorge E; Halliburton Terri A; Mallard Susie J; Estey Elihu H; Waddelow Tracey A; Lim JoAnn T
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
The Annals of pharmacotherapy 2003;37(9):1182-5.
2003: Tsimberidou Apostolia M; Colburn Dawn E; Welch Mary Alma; Cortes Jorge E; Verstovsek Srdan; O'Brien Susan M; Albitar Maher; Kantarjian Hagop M; Giles Francis J
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Cancer chemotherapy and pharmacology 2003;52(3):229-34.
2003: Giles Francis J; Shi Gary Guangping; Cortes Jorge E; Thomas Deborah; Keating Anna R; Kantarjian Hagop M; Keating Michael J; O'Brien Susan M
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Cancer chemotherapy and pharmacology 2003;52(3):223-8.
2003: Amin Hesham M; Jilani Iman; Estey Elihu H; Keating Michael J; Dey Amanda L; Manshouri Taghi; Kantarjian Hagop M; Estrov Zeev; Cortes Jorge E; Thomas Deborah A; Giles Francis J; Albitar Maher
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Ferrajoli Alessandra; O'Brien Susan M; Cortes Jorge E; Giles Francis J; Thomas Deborah A; Faderl Stefan; Kurzrock Razelle; Lerner Susan; Kontoyiannis Dimitrios P; Keating Michael J
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Issa Jean-Pierre; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Andreeff Michael; Keating Michael; Talpaz Moshe
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Giles Francis J; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Cooper Maureen A; Hannah Alison L; Cherrington Julie M; O'Farrell Anne-Marie; Yuen Helene A; Louie Sharianne G; Hong Weiru; Cortes Jorge E; Verstovsek Srdan; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M; Karp Judith E
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: O'Brien Susan; Giles Francis J
Monoclonal antibodies in the treatment of lymphoid leukemia.
Drugs of today (Barcelona, Spain : 1998) 2003;39(7):541-50.
2003: Giles Francis J; Miller Carole B; Hurd David D; Wingard John R; Fleming Thomas R; Sonis Stephen T; Bradford Williamson Z; Pulliam Janis G; Anaissie Elias J; Beveridge Roy A; Brunvand Mark M; Martin Paul J;
A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).
Leukemia & lymphoma 2003;44(7):1165-72.
2003: Cella David; Pulliam Janis; Fuchs Henry; Miller Carole; Hurd David; Wingard John R; Sonis Stephen T; Martin Paul J; Giles Francis
Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy.
Cancer 2003;98(2):406-12.
2003: Konopleva Marina; Cheng Su-Chun; Cortes Jorge E; Hayes Kimberly J; Pierce Sherry A; Andreeff Michael; Giles Francis J; O'Brien Susan; Kantarjian Hagop M; Estey Elihu H
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Thomas Deborah; Kornblau Steven; Shan Jianquin; Beth Rios Mary; Keating Michael; Freireich Emil; Talpaz Moshe
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Cancer 2003;98(1):81-5.
2003: Verstovsek Srdan; Lunin Scott; Kantarjian Hagop; Manshouri Taghi; Faderl Stefan; Cortes Jorge; Giles Francis; Albitar Maher
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Leukemia research 2003;27(7):661-9.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Freireich Emil J; Talpaz Moshe; Kantarjian Hagop
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Garcia-Manero Guillermo; Talpaz Moshe; Giles Francis J; Cortes Jorge; Faderl Stefan; O'Brien Susan; Thomas Deborah; Verstovsek Srdan; Beth Rios Mary; Shan Jianquin; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop M
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Albitar Maher; Rios Mary Beth; Talpaz Moshe; Garcia-Manero Guillermo; Faderl Stefan; Letvak Laurie; Salvado August; Kantarjian Hagop
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Tsimberidou A-M; Kantarjian H M; Estey E; Cortes J E; Verstovsek S; Faderl S; Thomas D A; Garcia-Manero G; Ferrajoli A; Manning J T; Keating M J; Albitar M; O'Brien S; Giles F J
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1100-3.
2003: Estey Elihu; Giles Francis; Cortes Jorge; Beran Miloslav; Verstovsek Srdan; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Giles Francis J; Bekele B Nebiyou; O'Brien Susan; Cortes Jorge E; Verstovsek Srdan; Balerdi Maria; Yared Marwan; Zhou Xian; Kantarjian Hagop M; Keating Michael J; Thall Peter; Albitar Maher
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Duzkale Hatice; Jilani Iman; Orsolic Nada; Zingaro Ralph A; Golemovic Mirna; Giles Francis J; Kantarjian Hagop; Albitar Maher; Freireich Emil J; Verstovsek Srdan
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines.
Cancer chemotherapy and pharmacology 2003;51(5):427-32.
2003: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Thomas Deborah A; Ferrajoli Alessandra; O'Brien Susan; Wathen Jay K; Xiao Lian-Chun; Berry Donald A; Estey Elihu H
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; White Kevin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Kornblau Steven; Cortes Jorge
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Verstovsek Srdan; Manshouri Taghi; Smith Franklin O; Giles Francis J; Cortes Jorge; Estey Elihu; Kantarjian Hagop; Keating Michael; Jeha Sima; Albitar Maher
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Cancer 2003;97(9):2212-7.
2003: Tsimberidou Apostolia Maria; Waddelow Tracey; Kantarjian Hagop M; Albitar Maher; Giles Francis J
Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
Leukemia research 2003;27(5):375-80.
2003: Cortes Jorge E; Talpaz Moshe; Giles Francis; O'Brien Susan; Rios Mary Beth; Shan Jianqin; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah A; Wierda William; Ferrajoli Allessandra; Jeha Sima; Kantarjian Hagop M
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Faderl Stefan; Thomas Deborah A; O'Brien Susan; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J; Koller Charles; Ferrajoli Alessandra; Verstovsek Srdan; Pro Barbara; Andreeff Michael; Beran Miloslav; Cortes Jorge; Wierda William; Tran Ngoc; Keating Michael J
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Leopold Lance H; Berger Mark S; Cheng Su-Chun; Cortes-Franco Jorge E; Giles Francis J; Estey Elihu H
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Clinical advances in hematology & oncology : H&O 2003;1(4):220-5.
2003: Giles Francis J; Cooper Maureen A; Silverman Lewis; Karp Judith E; Lancet Jeffrey E; Zangari Maurizio; Shami Paul J; Khan Khuda D; Hannah Alison L; Cherrington Julie M; Thomas Deborah A; Garcia-Manero Guillermo; Albitar Maher; Kantarjian Hagop M; Stopeck Alison T
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2003: Ibrahim Sherif; Jilani Iman; O'Brien Susan; Rogers Anna; Manshouri Taghi; Giles Francis; Faderl Stefan; Thomas Deborah; Kantarjian Hagop; Keating Michael; Albitar Maher
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Cancer 2003;97(8):1914-9.
2003: Tsimberidou Apostolia M; Kantarjian Hagop M; Cortes Jorge; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Ferrajoli Alessandra; Wierda William; Alvarado Yesid; O'Brien Susan M; Albitar Maher; Keating Michael J; Giles Francis J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Apostolidou Efrosyni; Estey Elihu; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Tsimberidou Apostolia; Kantarjian Hagop; Giles Francis J
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Leukemia research 2003;27(4):301-4.
2003: Manshouri Taghi; Do Kim-anh; Wang Xuemei; Giles Francis J; O'Brien Susan M; Saffer Helen; Thomas Deborah; Jilani Iman; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Blood 2003;101(7):2507-13.
2003: Kantarjian Hagop M; Gandhi Varsha; Kozuch Peter; Faderl Stefan; Giles Francis; Cortes Jorge; O'Brien Susan; Ibrahim Nuhad; Khuri Fadlo; Du Min; Rios Mary Beth; Jeha Sima; McLaughlin Peter; Plunkett William; Keating Michael
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Giles Francis J; Faderl Stefan; Thomas Deborah A; Cortes Jorge E; Garcia-Manero Guillermo; Douer Dan; Levine Alexandra M; Koller Charles A; Jeha Sima S; O'Brien Susan M; Estey Elihu H; Kantarjian Hagop M
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Tsimberidou A-M; Medina J; Earl M; Sierra M; Shriki J E; Bueso-Ramos C; Giralt S; Beran M; Giles F J; Garcia-Manero G
Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia.
Bone marrow transplantation 2003;31(5):413-4.
2003: Mattiuzzi Gloria N; Cortes Jorge E; Talpaz Moshe; Reuben James; Rios Mary Beth; Shan Jianjin; Kontoyiannis Dimitrios; Giles Francis J; Raad Issam; Verstovsek Srdan; Ferrajoli Alessandra; Kantarjian Hagop M
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Tsimberidou Apostolia; Estey Elihu; Cortes Jorge; Thomas Deborah; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Keating Michael; Albitar Maher; O'Brien Susan; Kantarjian Hagop; Giles Francis
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; Cortes Jorge; Faderl Stefan; Giles Francis J; Keating Michael; Albitar Maher
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Cancer 2003;97(5):1248-52.
2003: Cortes Jorge; Kantarjian Hagop; Albitar Maher; Thomas Deborah; Faderl Stefan; Koller Charles; Garcia-Manero Guillermo; Giles Francis; Andreeff Michael; O'Brien Susan; Keating Michael; Estey Elihu
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Cortes Jorge; Albitar Maher; Thomas Deborah; Giles Francis; Kurzrock Razelle; Thibault Alain; Rackoff Wayne; Koller Charles; O'Brien Susan; Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2003: Colburn Dawn E; Thomas Deborah A; Giles Francis J
Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia.
Investigational new drugs 2003;21(1):109-11.
2003: Aguayo Alvaro; Giles Francis; Albitar Maher
Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes.
Leukemia & lymphoma 2003;44(2):213-22.
2003: Wierda William G; Johnson Marcella M; Do Kim-Anh; Manshouri Taghi; Dey Amanda; O'Brien Susan; Giles Francis J; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Lerner Susan; Keating Michael; Albitar Maher
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
British journal of haematology 2003;120(3):452-6.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Shan Jianqin; Giles Francis J; Rios Mary Beth; Faderl Stefan H; Wierda William G; Ferrajoli Alessandra; Verstovsek Srdan; Keating Michael J; Freireich Emil J; Talpaz Moshe
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Kantarjian Hagop M; Talpaz Moshe; Cortes Jorge; O'Brien Susan; Faderl Stefan; Thomas Deborah; Giles Francis; Rios Mary Beth; Shan Jianqin; Arlinghaus Ralph
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):160-6.
2003: Jilani I; Estey E; Manshuri T; Caligiuri M; Keating M; Giles F; Thomas D; Kantarjian H; Albitar M
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):114-9.
2003: Mattiuzzi Gloria N; Estey Elihu; Raad Issam; Giles Francis; Cortes Jorge; Shen Yu; Kontoyiannis Dimitrios; Koller Charles; Munsell Mark; Beran Miloslav; Kantarjian Hagop
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):450-6.
2003: Alvarado Yesid; Tsimberidou Apostolia; Kantarjian Hagop; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Estey Elihu; Giles Francis J
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2003;51(1):87-90.
2003: Alvarado Yesid; Cortes Jorge; Verstovsek Srdan; Thomas Deborah; Faderl Stephan; Estrov Zeev; Kantarjian Hagop; Giles Francis J
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
Cancer chemotherapy and pharmacology 2003;51(1):81-6.
2003: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Jeha Sima; Rios Mary Beth; Letvak Laurie; Bochinski Kathy; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2003: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Giles Francis J
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Expert review of anticancer therapy 2002;2(6):630-40.
2002: Tsimberidou Apostolia-Maria; Giles Francis J
Essential thrombocythemia (ET): moving from palliation to cure.
Hematology (Amsterdam, Netherlands) 2002;7(6):315-23.
2002: Cortes Jorge; Tsimberidou Apostolia M; Alvarez Ricardo; Thomas Deborah; Beran Miloslav; Kantarjian Hagop; Estey Elihu; Giles Francis J
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2002;50(6):497-500.
2002: Aguayo Alvaro; Kantarjian Hagop M; Estey Elihu H; Giles Francis J; Verstovsek Srdan; Manshouri Taghi; Gidel Christy; O'Brien Susan; Keating Michael J; Albitar Maher
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Huh Y O; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(11):2249-52.
2002: Alvarado Yesid; Bellm Lisa A; Giles Francis J
Oral mucositis: time for more studies.
Hematology (Amsterdam, Netherlands) 2002;7(5):281-9.
2002: Giles Francis J
Leukapheresis in patients with previously untreated acute myeloid leukemia.
Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis 2002;6(5):399-400.
2002: Jilani Iman; Estey Elihu; Huh Yang; Joe Youngson; Manshouri Taghi; Yared Marwan; Giles Francis; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Keating Michael; Freireich Emil; Albitar Maher
Differences in CD33 intensity between various myeloid neoplasms.
American journal of clinical pathology 2002;118(4):560-6.
2002: Giles Francis; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Kantarjian Hagop; Estey Elihu
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
Haematologica 2002;87(10):1114-6.
2002: Giles Francis J; Kantarjian Hagop M; Bekele B Nebiyou; Cortes Jorge E; Faderl Stephan; Thomas Deborah A; Manshouri Taghi; Rogers Anna; Keating Michael J; Talpaz Moshe; O'Brien Susan; Albitar Maher
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Tsimberidou Apostolia-Maria; Thomas Deborah; O'Brien Susan; Andreeff Michael; Kurzrock Razelle; Keating Michael; Albitar Maher; Kantarjian Hagop; Giles Francis
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Cancer chemotherapy and pharmacology 2002;50(3):237-42.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Giralt Sergio A; Rios Mary Beth; Shan Jianqin; Giles Francis J; Thomas Deborah A; Faderl Stefan; De Lima Marcos; Garcia-Manero Guillermo; Champlin Richard; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Giles Francis J
New drugs in acute myeloid leukemia.
Current oncology reports 2002;4(5):369-74.
2002: Tsimberidou Apostolia-Maria; Alvarado Yesid; Giles Francis J
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Expert review of anticancer therapy 2002;2(4):437-48.
2002: Garcia-Manero Guillermo; Faderl Stefan; Giles Francis; Thomas Deborah; Cortes Jorge; O'Brien Susan; Davis Jan; Kantarjian Hagop M; Estey Elihu
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Giles Francis J; Redman Rebecca; Yazji Salim; Bellm Lisa
Iseganan HCl: a novel antimicrobial agent.
Expert opinion on investigational drugs 2002;11(8):1161-70.
2002: Ferrajoli Alessandra; Keating Michael J; Manshouri Taghi; Giles Francis J; Dey Amanda; Estrov Zeev; Koller Charles A; Kurzrock Razelle; Thomas Deborah A; Faderl Stefan; Lerner Susan; O'Brien Susan; Albitar Maher
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Smith Terry L; Giles Francis J; Faderl Stefan; Thomas Deborah A; Garcia-Manero Guillermo; Issa Jean-Pierre J; Andreeff Michael; Kornblau Steven M; Koller Charles; Beran Milosav; Keating Michael; Rios Mary Beth; Shan Jenny; Resta Debra; Capdeville Renaud; Hayes Kimberly; Albitar Maher; Freireich Emil J; Cortes Jorge E
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Smith Terry L; Rios Mary Beth; Shan Jianqin; Yang Ying; Giles Francis J; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Jeha Sima; Wierda William; Issa Jean-Pierre J; Kornblau Steven M; Keating Michael; Resta Debra; Capdeville Renaud; Talpaz Moshe
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Giles Francis J; Cortes Jorge E; Thomas Deborah A; Garcia-Manero Guillermo; Faderl Stephan; Jeha Sima; De Jager Robert L; Kantarjian Hagop M
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2134-41.
2002: Verstovsek Srdan; Estey Elihu; Manshouri Taghi; Giles Francis J; Cortes Jorge; Beran Miloslav; Rogers Anna; Keating Michael; Kantarjian Hagop; Albitar Maher
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
British journal of haematology 2002;118(1):151-6.
2002: Ravandi Farhad; Cortes Jorge; Estrov Zeev; Thomas Deborah; Giles Francis J; Huh Yang O; Pierce Sherry; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Leukemia research 2002;26(7):643-9.
2002: Colburn Dawn E; Welch Mary-Alma; Giles Francis J
Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis.
Hematology (Amsterdam, Netherlands) 2002;7(3):187-8.
2002: Alvarado Yesid; Kantarjian Hagop M; Cortes Jorge E; Apostolidou Efrosynl; Bivins Carol; Giles Francis J
Troxacitabine activity in extramedullary myeloid leukemia.
Hematology (Amsterdam, Netherlands) 2002;7(3):179-85.
2002: Tsimberidou Apostolia-Maria; Giles Francis J
TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.
Expert review of anticancer therapy 2002;2(3):277-86.
2002: Giles Francis J
Troxacitabine-based therapy of refractory leukemia.
Expert review of anticancer therapy 2002;2(3):261-6.
2002: Estey Elihu H; Thall Peter F; Giles Francis J; Wang Xue-Mei; Cortes Jorge E; Beran Miloslav; Pierce Sherry A; Thomas Deborah A; Kantarjian Hagop M
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Estey Elihu H; Giles Francis J; Beran Miloslav; O'Brien Susan; Pierce Sherry A; Faderl Stefan H; Cortes Jorge E; Kantarjian Hagop M
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Mohrbacher Ann F; Gregory Stephanie A; Gabriel Don A; Rusk Jason M; Giles Francis J
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
Cancer 2002;94(10):2645-52.
2002: Giles Francis J
The emerging role of angiogenesis inhibitors in hematologic malignancies.
Oncology (Williston Park, N.Y.) 2002;16(5 Suppl 4):23-9.
2002: Kantarjian Hagop M; Cortes Jorge; O'Brien Susan; Giles Francis J; Albitar Maher; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Resta Debra; Talpaz Moshe
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Tsimberidou Apostolia M; O'Brien Susan M; Cortes Jorge E; Faderl Stefan; Andreeff Michael; Kantarjian Hagop M; Keating Michael J; Giles Francis J
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: O'Brien Susan; Talpaz Moshe; Cortes Jorge; Shan Jianqin; Giles Francis J; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Mallard Susie; Beth Mary; Koller Charles; Kornblau Steve; Andreeff Michael; Murgo Anthony; Keating Michael; Kantarjian Hagop M
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; Cortes Jorge; Giles Francis J; Rogers Anna; Albitar Maher
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.
Blood 2002;99(6):2265-7.
2002: Hui Yuk Fung; Giles Francis J; Cortes Jorge E
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.
Investigational new drugs 2002;20(1):49-53.
2002: Surapaneni Usha R; Cortes Jorge E; Thomas Deborah; O'Brien Susan; Giles Francis J; Koller Charles; Faderl Stefan; Kantarjian Hagop
Central nervous system relapse in adults with acute lymphoblastic leukemia.
Cancer 2002;94(3):773-9.
2002: Giles Francis J; Garcia-Manero Guillermo; Cortes Jorge E; Baker Sharyn D; Miller Carol B; O'Brien Susan M; Thomas Deborah A; Andreeff Michael; Bivins Carol; Jolivet Jacques; Kantarjian Hagop M
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):656-64.
2002: Giles Francis J
Novel agents for the therapy of acute leukemia.
Current opinion in oncology 2002;14(1):3-9.
2002: Giles Francis J; Keating Armand; Goldstone Anthony H; Avivi Irit; Willman Cheryl L; Kantarjian Hagop M
Acute myeloid leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():73-110.
2002: Giles Francis; Garcia-Manero Guillermo; O'Brien Susan; Estey Eihu; Kantarjian Hagop
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Acta haematologica 2002;108(3):164-7.
2001: Estey E H; Thall P F; Cortes J E; Giles F J; O'Brien S; Pierce S A; Wang X; Kantarjian H M; Beran M
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Kantarjian H M; Shan J; Smith T; Talpaz M; Kozuch P; Rios M B; Cortes J; Giles F J; O'Brien S
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Cortes J; O'Brien S; Loscertales J; Kantarjian H; Giles F; Thomas D; Koller C; Keating M
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Cancer 2001;92(8):2016-22.
2001: Beran M; Shen Y; Kantarjian H; O'Brien S; Koller C A; Giles F J; Cortes J; Thomas D A; Faderl S; Despa S; Estey E H
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles F J; Faderl S; Kantarjian H M
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Verstovsek S; Kantarjian H; Estey E; Aguayo A; Giles F J; Manshouri T; Koller C; Estrov Z; Freireich E; Keating M; Albitar M
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(8):1165-70.
2001: Verstovsek S; Estey E; Manshouri T; Keating M; Kantarjian H; Giles F J; Albitar M
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Leukemia & lymphoma 2001;42(3):511-6.
2001: Dabaja B S; O'Brien S M; Kantarjian H M; Cortes J E; Thomas D A; Albitar M; Schlette E S; Faderl S; Sarris A; Keating M J; Giles F J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: Estey E; Koller C; Cortes J; Reed P; Freireich E; Giles F; Kantarjian H
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Leukemia & lymphoma 2001;42(3):309-16.
2001: Giles F J; Kantarjian H M; Kornblau S M; Thomas D A; Garcia-Manero G; Waddelow T A; David C L; Phan A T; Colburn D E; Rashid A; Estey E H
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer 2001;92(2):406-13.
2001: Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cancer 2001;92(1):7-14.
2001: Giles F J; Shen Y; Kantarjian H M; Korbling M J; O'Brien S; Anderlini P; Donato M; Pierce S; Keating M J; Freireich E J; Estey E
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Ravandi F; Kantarjian H M; Talpaz M; O'Brien S; Faderl S; Giles F J; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios M B; Albitar M
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Verstovsek S; Manshouri T; Kantarjian H; Giles F J; Keating M; Estey E; Albitar M
Highly reproducible detection and semi-quantification of telomerase activity.
BioTechniques 2001;30(5):930-4.
2001: Giles F J; Kantarjian H; O'Brien S; Rios M B; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Leukemia & lymphoma 2001;41(3-4):309-19.
2001: O'Brien S M; Kantarjian H; Thomas D A; Giles F J; Freireich E J; Cortes J; Lerner S; Keating M J
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2165-70.
2001: Schlette E; Bueso-Ramos C; Giles F; Glassman A; Hayes K; Medeiros L J
Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma.
American journal of clinical pathology 2001;115(4):571-81.
2001: Beck J R; Guilhot J; Giles F J; Aoki N; Wirt D P; Guilhot F
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Leukemia & lymphoma 2001;41(1-2):117-24.
2001: O'Brien S M; Kantarjian H M; Cortes J; Beran M; Koller C A; Giles F J; Lerner S; Keating M
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1414-20.
2001: Smolich B D; Yuen H A; West K A; Giles F J; Albitar M; Cherrington J M
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Blood 2001;97(5):1413-21.
2001: Wirt D P; Giles F J; Oken M M; Solal-Celigny P; Beck J R
Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Leukemia & lymphoma 2001;40(5-6):565-79.
2001: Giles F J; Cortes J E; Baker S D; Thomas D A; O'Brien S; Smith T L; Beran M; Bivins C; Jolivet J; Kantarjian H M
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):762-71.
2001: Thomas D A; Giles F J; Cortes J; Albitar M; Kantarjian H M
Antiangiogenic therapy in leukemia.
Acta haematologica 2001;106(4):190-207.
2001: Giles F J
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
The oncologist 2001;6 Suppl 5():32-9.
2001: Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Investigational new drugs 2001;19(1):13-20.
2000: Giles F J; Shan J; Advani S H; Akan H; Aydogdu I; Aziz Z; Azim H A; Bapsy P P; Buyukkececi F; Chaimongkol B; Chen P M; Cheong S K; Ferhanoglu B; Hamza R; Khalid H M; Intragumtornchai T; Kim S W; Kim S Y; Koc H; Kumar L; Kumar R; Lei K I; Lekhakula A; Muthalib A; Patel M; Poovalingam V P; Prayoonwiwat W; Rana F; Reksodiputro A H; Ruff P; Sagar T G; Schwarer A P; Song H S; Suh C W; Suharti C; Supindiman I; Tee G Y; Thamprasit T; Villalon A H; Wickham N R; Wong J E; Yalcin A; Jootar S;
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Leukemia & lymphoma 2000;40(1-2):95-103.
2000: Kantarjian H M; Giles F J; O'Brien S; Giralt S; Talpaz M
Therapeutic choices in younger patients with chronic myelogenous leukemia.
Cancer 2000;89(8):1647-58.
2000: Kantarjian H M; Talpaz M; Smith T L; Cortes J; Giles F J; Rios M B; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: Sriswasdi C; Jootar S; Giles F J
Amifostine and hematologic effects.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2000;83(4):374-82.
2000: Giles F J; Shan J; Chen S; Advani S H; Supandiman I; Aziz Z; Caviles A P; Tee G Y; Chasen M R; Fahed Z; Chaoj T Y; Aydogdu I; Lynott A M
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
Leukemia & lymphoma 2000;37(3-4):367-77.
2000: Giles F J; Wong G C; Clark S J; Pierce S; Kantarjian H M; Keating M J
Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):87-95.
2000: Giles F J; Wickham N R; Rapoport B L; Somlo G; Lim S W; Shan J; Lynott A M
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
American journal of hematology 2000;63(3):125-30.
2000: Ravandi-Kashani F; Cortes J; Giles F J
Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome.
Leukemia & lymphoma 2000;36(5-6):631-7.
2000: Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia & lymphoma 2000;36(5-6):479-84.
2000: Vey N; Giles F J; Kantarjian H; Smith T L; Beran M; Jeha S
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):731-6.
2000: Kantarjian H M; O'Brien S; Smith T L; Cortes J; Giles F J; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha C S; Keating M J; Murphy S; Freireich E J
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
2000: Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles F J; Pierce S; Albitar M
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Cancer 2000;88(3):570-6.
2000: Faderl S; Kantarjian H M; Thomas D A; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Leukemia & lymphoma 2000;36(3-4):263-73.
1999: Kantarjian H M; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios M B; Croce C M; Albitar M
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Giles F J; O'Brien S M; Santini V; Gandhi V; Plunkett W; Seymour J F; Robertson L E; Kantarjian H M; Keating M J
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Sacchi S; Kantarjian H M; O'Brien S; Cortes J; Rios M B; Giles F J; Beran M; Koller C A; Keating M J; Talpaz M
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Aguayo A; Estey E; Kantarjian H; Mansouri T; Gidel C; Keating M; Giles F; Estrov Z; Barlogie B; Albitar M
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood 1999;94(11):3717-21.
1999: Sacchi S; Kantarjian H M; Freireich E J; O'Brien S; Cortes J; Rios M B; Kornblau S; Giles F J; Koller C; Gajewski J; Talpaz M
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Giles F J; Keating A R; Kurzrock R; Talpaz M
A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(11):1253-5.
1999: Santini V; Giles F J
The potential of amifostine: from cytoprotectant to therapeutic agent.
Haematologica 1999;84(11):1035-42.
1999: Thomas D A; Kantarjian H; Smith T L; Koller C; Cortes J; O'Brien S; Giles F J; Gajewski J; Pierce S; Keating M J
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-30.
1999: Estey E H; Giles F J; Kantarjian H; O'Brien S; Cortes J; Freireich E J; Lopez-Berestein G; Keating M
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: Beran M; Estey E; O'Brien S; Cortes J; Koller C A; Giles F J; Kornblau S; Andreeff M; Vey N; Pierce S R; Hayes K; Wong G C; Keating M; Kantarjian H
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2819-30.
1999: Giles F J; Kantarjian H M; Cortes J; Thomas D A; Talpaz M; Manshouri T; Albitar M
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Cancer 1999;86(5):805-13.
1999: Ravandi-Kashani F; Estey E; Cortes J; Medeiros L J; Giles F J
Granulocytic sarcoma of the pancreas: a report of two cases and literature review.
Clinical and laboratory haematology 1999;21(3):219-24.
1999: Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):577-83.
1999: Vey N; Keating M; Giles F; Cortes J; Beran M; Estey E
Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.
Blood 1999;93(9):3149-50.
1999: Cortes J E; Kantarjian H M; O'Brien S; Giles F; Keating M J; Freireich E J; Estey E H
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Kantarjian H M; O'Brien S; Smith T L; Rios M B; Cortes J; Beran M; Koller C; Giles F J; Andreeff M; Kornblau S; Giralt S; Keating M J; Talpaz M
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1999: Cortes J; O'Brien S; Estey E; Giles F; Keating M; Kantarjian H
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Investigational new drugs 1999;17(1):81-7.
1998: Beran M; Estey E; O'Brien S M; Giles F J; Koller C A; Kornblau S; Keating M; Kantarjian H M
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia & lymphoma 1998;31(5-6):521-31.
1998: Giles F J; Kanemaki T J; Schreck R R; Qasabian L; Fuerst M P; Lim S W
Translocation (3;21;8)(q21;q22;q22) in a patient with acute myeloid leukemia. A case report and review of prognostic indicators.
Cancer genetics and cytogenetics 1998;104(1):66-9.
1998: Giles F J
Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(6):1282-9.
1998: Ozer H; Wiernik P H; Giles F; Tendler C
Recombinant interferon-alpha therapy in patients with follicular lymphoma.
Cancer 1998;82(10):1821-30.
1998: Kantarjian H M; Giles F J; O'Brien S M; Talpaz M
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
Hematology/oncology clinics of North America 1998;12(1):31-80.
1998: Giles F J; O'Brien S M; Keating M J
Chronic lymphocytic leukemia in (Richter's) transformation.
Seminars in oncology 1998;25(1):117-25.
1997: Giles F J; Waxman A D; Nguyen K N; Fuerst M P; Kusuanco D A; Franco M M; Bierman H; Lim S W
Comparison of Technetium-99m sestamibi and indium-111 octreotide imaging in a patient with Ewing's sarcoma before and after stem cell transplantation.
Cancer 1997;80(12 Suppl):2478-83.
1997: Levine A M; Tulpule A; Tessman D; Kaplan L; Giles F; Luskey B D; Scadden D T; Northfelt D W; Silverberg I; Wernz J; Espina B; Von Hoff D
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1094-103.
1997: Jewell A P; Worman C P; Giles F J; Goldstone A H
Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy.
Leukemia & lymphoma 1997;24(3-4):327-33.
1996: Kattan M W; Inoue Y; Giles F J; Talpaz M; Ozer H; Guilhot F; Zuffa E; Huber S L; Beck J R
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
Annals of internal medicine 1996;125(7):541-8.
1996: Jewell A P; Giles F J
Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia.
Leukemia & lymphoma 1996;21(3-4):347-9.
1996: Look R M; Lim S W; Waxman A D; Gupta P K; Fuerst M M; Kusuanco D A; Lawrence G N; Giles F J
Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantation.
Leukemia & lymphoma 1996;20(5-6):453-6.
1996: Lim S W; Falk R E; Look R M; Fuerst M M; Lawrence G N; Kusuanco D A; Giles F J
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Cancer genetics and cytogenetics 1996;86(2):165-7.
1995: Giles F J
Current therapy of refractory multiple myeloma.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():88-105.
1995: Look R M; Lim S W; Schreck R R; Lee S; Fuerst M P; Lawrence G N; Kusuanco D A; Kessler C E; Giles F J
Burkitt translocation (8;22)(q24;q11) in a patient with multiple myeloma.
Cancer genetics and cytogenetics 1995;82(2):100-2.
1995: Jewell A P; Lydyard P M; Worman C P; Giles F J; Goldstone A H
Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation.
Leukemia & lymphoma 1995;18(1-2):159-62.
1995: Giles F J
Refractory multiple myeloma: recent advances in therapy.
Hematologic pathology 1995;9(3-4):121-40.
1994: Jewell A P; Worman C P; Lydyard P M; Yong K L; Giles F J; Goldstone A H
Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo.
British journal of haematology 1994;88(2):268-74.
1994: McSweeney E N; Giles F J; Goldstone A H
Recombinant interferon-alpha 2 antibodies in chronic lymphocytic leukemia.
Journal of interferon research 1994;14(4):191-2.
1994: Giles F J
Multiple myeloma and other differentiated B-cell disorders.
Current opinion in hematology 1994;1(4):278-84.
1994: Giles F J; Koeffler H P
Secondary myelodysplastic syndromes and leukemias.
Current opinion in hematology 1994;1(4):256-60.
1994: Jewell A P; Yong K L; Worman C P; Tsakona C P; Giles F J; Goldstone A H
Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL.
British journal of haematology 1994;86(2):441-3.
1993: McSweeney E N; Giles F J; Worman C P; Jewel A P; Tsakona C P; Hoffbrand A V; Mehta A B; Newland A C; Cawley J C; Galvani D
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia.
British journal of haematology 1993;85(1):77-83.
1992: Jewell A P; Worman C P; Giles F J; Goldstone A H; Lydyard P M
Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Leukemia & lymphoma 1992;7(5-6):473-80.
1992: Giles F J; Aitchison R; Syndercombe-Court D; Schey S; Newland A C
Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia.
Leukemia & lymphoma 1992;7(1-2):99-102.
1992: Jewell A P; Yong K L; Worman C P; Giles F J; Goldstone A H; Lydyard P M
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(5):400-4.
1992: Giles F J; McSweeney E N; Richards J D; Tobias J S; Gaminara E J; Grant I R; Kearney J W; Newland A C; Parker N E; Schey S
Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1392-5.
1991: Giles F J; Ozer H
alpha-Interferon in hematological malignancies.
Current opinion in biotechnology 1991;2(6):847-50.
1991: Giles F J
Maintenance therapy in the myeloproliferative disorders: the current options.
British journal of haematology 1991;79 Suppl 1():92-5.
1991: McCarthy D; Clark J; Giles F
The treatment of myelofibrosis with alfa-interferon.
British journal of haematology 1991;78(4):590-1.
1991: Lim S H; Giles F J; Smith M P; Goldstone A H
Bacterial infections in lymphoma patients treated with recombinant interleukin-2.
Acta haematologica 1991;85(3):135-8.
1991: Lim S H; Worman C; Jewell A; Tsakona C; Giles F J; Goldstone A
Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.
Cancer immunology, immunotherapy : CII 1991;33(2):133-7.
1991: Giles F J; Worman C P; Jewell A P; Goldstone A H
Recombinant alpha-interferons, thyroid irradiation and thyroid disease.
Acta haematologica 1991;85(3):160-3.
1990: de Mel W C; Hoffbrand A V; Giles F J; Goldstone A H; Mehta A B; Ganeshaguru K
Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response.
British journal of haematology 1990;74(4):452-6.
1990: Giles F J; Smith M P; Goldstone A H
Chlorambucil lung toxicity.
Acta haematologica 1990;83(3):156-8.
1989: Kinsey S E; Giles F J; Holton J
Cusum plotting of temperature charts for assessing antimicrobial treatment in neutropenic patients.
BMJ (Clinical research ed.) 1989;299(6702):775-6.
1989: Martiat P; Ifrah N; Rassool F; Morgan G; Giles F; Gow J; Goldman J M
Molecular analysis of Philadelphia positive essential thrombocythemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(8):563-5.
1989: Singer C R; Tobias J S; Giles F; Rudd G N; Blackman G M; Richards J D
Hemibody irradiation. An effective second-line therapy in drug-resistance multiple myeloma.
Cancer 1989;63(12):2446-51.
1988: Maurice P D; Bunker C; Giles F; Goldstone A; Holton J
Mycobacterium avium-intracellulare infection associated with hairy-cell leukemia.
Archives of dermatology 1988;124(10):1545-9.
1988: Russell S J; Giles F J; Thompson D S; Scanlon D J; Walker H; Richards J D
Granulocytic sarcoma of the small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16).
Cancer genetics and cytogenetics 1988;35(2):231-5.
1988: Russell S J; Walker H; Giles F J; Goldstone A H
Ring chromosome 6 and i(17q-) in a patient with acute promyelocytic leukemia. Absence of translocation t(15;17).
Cancer genetics and cytogenetics 1988;34(2):273-6.
1988: Giles F J; Singer C R; Gray A G; Yong K L; Brozovic M; Davies S C; Grant I R; Hoffbrand A V; Machin S J; Mehta A B
Alpha-interferon therapy for essential thrombocythaemia.
Lancet 1988;2(8602):70-2.
1988: Giles F J; Russell S J; Worman C P; Goldstone A H; Richards J D; Holton J
Atypical mycobacterial infection in alpha interferon-treated hairy cell leukaemia.
Acta haematologica 1988;80(3):159-61.
1987: Russell S J; Giles F J; Edwards D; Porter J; Hardmann S; Harrison R
Perforation of superior vena cava by indwelling central venous catheters.
Lancet 1987;1(8532):568-9.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Francis Giles

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Francis Giles (preview)

All Publications